India's Syngene International on Monday said it has acquired its first biologics facility in the United States from Emergent ...

(Corrects deal value in headline, paragraph 1 to $36.5 million, from $50 million)(Reuters) -India's Syngene International on ...

Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...

Biocon Biologics, one of India's leading biologic drug manufacturers, announced on Friday the results of a Phase-3 study on a ...

Biocon arm Syngene International announced today the acquisition of its first biologics facility in the USA from Emergent ...

Syngene International acquires US manufacturing facility, expanding bioreactor capacity and global service capabilities for pharmaceutical innovation.

Introduction of a direct-to-patient delivery model for its weight-loss drug in the United States could potentially delay its ...

Shares of firms like HCL Tech, RailTel, Tata Power, IndusInd Bank, Gensol, and others will be in focus on Monday's trade ...

Nifty March Futures up by 0.08% at a premium of 97.45 points. Nifty Options March 13 Expiry: Maximum call open interest at 20 ...

Stocks like India Pesticides, HFCL, NDR Auto Components, JSW Steel, GR Infraprojects, Biocon, Oil and Natural Gas Corporation, Container Corporation of India, Thangamayil Jewellery, Hinduja Global ...

An Indian healthcare company has acquired its first US facility investing around US$50 million. It is a global contract research, development, and manufacturing organization (CRDMO). The company has ...

The resurgence of the M23 (March 23 movement) rebel group has once again drawn global attention to the eastern Democratic ...